Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type i receptor selective antagonist

Neuropsychopharmacology

Volumn 27, Issue 2, 2002, Pages 194-202

  Heinrichs, Stephen C ^a   De Souza, Errol B ^b   Schulteis, Gery ^c   Lapsansky, Jeanette L ^a   Grigoriadis, Dimitri E ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b SANOFI   (France)

^c University of California   (United States)

Author keywords

Anxiety; Axiolytic; CRF; Pituitary adrenal; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DOSE RESPONSE; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SCREENING; FORCED SWIMMING TEST; HYPOPHYSIS ADRENAL SYSTEM; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; STRESS; WITHDRAWAL SYNDROME;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MAZE LEARNING; PITUITARY-ADRENAL SYSTEM; PYRIMIDINES; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS;

EID: 0036289254     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00299-3     Document Type: Article

References (34)

1. Non-peptidic corticotropin-releasing hormone receptor type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: Evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1
2. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats
3. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression
4. Corticotropin-releasing factor receptors: From molecular biology to drug design
5. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents
6. 125I-Tyr0-Sauvagine: A novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2α receptors
7. In vitro characterization of R121919: A novel non-peptide corticotropin-releasing factor1 (CRF1) receptor antagonist for the potential treatment of depression and anxiety-related disorders. Society for Neuroscience
8. Application of experimental stressors in laboratory rodents.
9. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior
10. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity
11. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
12. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal
13. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats
14. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors
15. Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats
16. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain
17. A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity
18. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
19. Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications
20. Allostasis and allostatic load: Implications for neuropsychopharmacology
21. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats
22. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent
23. Urocortin, a novel neuropeptide with anxiogenic-like properties
24. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions
25. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001
26. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat
27. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat
28. Corticotropin-releasing factor (CRF) antagonist [D-Phe 12, NLE21,38, CalphaMeLeu37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats
29. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
30. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
31. Corticotropin-releasing hormone receptor subtypes and emotion
32. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats
33. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor
34. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated